Drug Profile
Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India
Alternative Names: Adalimumab biosimilar - Neuclone/Serum Institute of India; Palivizumab biosimilar - Neuclone/Serum Institute of IndiaLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator NeuClone; Serum Institute of India
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antihypercalcaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Antiulcers; Antivirals; Calcium regulators; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; ERBB 2 receptor antagonists; Immunomodulators; RANK ligand inhibitors; Tumour necrosis factor alpha inhibitors; Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in Australia (Parenteral)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in India (Parenteral)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)